Benitec grants license in Ambion settlement
Tuesday, 10 August, 2004
Benitec (ASX: BLT) has settled its patent infringement case against US company Ambion, giving the company a world-wide non-exclusive licence to make and sell DNA-directed RNAi products.
The suit, which was originally filed on March 22, 2004 in the US, was settled out of court. Details of the settlement and licence have not been released by the company.
The Ambion suit was first announced in March, along with two other lawsuits filed against Nucleonics and Genscript Corporation.
"We will continue to protect our issued RNAi patent estate whilst enabling the widest usage of this important technology for both research and commercial therapeutic purposes," said CEO John McKinley in a statement.
Abnormal brain protein targeted in Parkinson's study
Researchers have identified a new brain protein involved in the development of Parkinson's...
Epilepsy disease model treated in a laboratory dish
A research team has used an epilepsy-like disease model in a laboratory dish to demonstrate that...
Newborns have elevated levels of an Alzheimer's biomarker
What do the brains of newborns and patients with Alzheimer's disease have in common? Both...
